Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 May;71(5):2168-2174.
doi: 10.4103/IJO.IJO_2548_22.

The efficacy of anti-TNF-α agents in the treatment of juvenile idiopathic arthritis-associated uveitis in a pediatric cohort

Mai Nasser Abd ElMohsen  1 , Lameece Moustafa Hassan, Maha Mohamed Youssef, Shereen H Aboul Naga
Affiliations
Comment

The efficacy of anti-TNF-α agents in the treatment of juvenile idiopathic arthritis-associated uveitis in a pediatric cohort

Mai Nasser Abd ElMohsen et al. Indian J Ophthalmol. 2023 May.

Abstract

Purpose: Biologic therapy has shown promising control in children with often intractable juvenile idiopathic arthritis (JIA)-associated uveitis (JIA-U).

Methods: This is a retrospective cohort study of 35 eyes of 35 children who received biologics for JIA-U. Pretreatment and posttreatment data (at 3, 6, 9, 12, 18, 24, and >24 months) were analyzed to determine functional success (stable/improved visual acuity), quiescence success (≤0.5 cells in the anterior chamber), complete steroid success (termination of systemic, periocular therapy and decreased topical drops to ≤2/day) or systemic steroid success (termination of systemic steroids only), and complete success (all of the above).

Results: This study included 35 eyes up to 12 months and 21 eyes beyond 24 months. Steroid-sparing, functional, and quiescence success showed a rate of success of 52.43%, 77%, and 91%, respectively, at 12 months and 66.67%, 85.7%, and 76.2%, respectively, beyond 24 months. Complete success was 34.29% at 12 months, peaking at 18 months (65.62%) and reached 57.14% beyond 24 months. In their final follow-up, the best corrected visual acuity (BCVA) remained the same in 45.71%, improved in 37.14%, and worsened in 17.14% children.

Conclusion: Biologic therapy is effective in JIA-U, especially in termination of systemic steroids, stabilization of vision, and maintaining quiescence.

Keywords: Adalimumab; JIA-U; biologics; etanercept; immunosuppressive therapy; infliximab; pediatrics; uveitis.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
(a) Distribution of different types of success over the study period. (b) Overview of steroid success trend among the three patient subgroups. JIA = juvenile idiopathic arthritis
See this image and copyright information in PMC

Comment on

References

    1. Thorne E, Woreta F, Kedhar SK, Dunn JP, Jabs DA. Juvenile idiopathic arthritis-associated uveitis:Incidence of ocular complications and visual acuity loss. Am JOphthalmol. 2005;143:840–6. - PubMed
    1. Qian Y, Acharya NR. Juvenile idiopathic arthritis associated uveitis. CurrOpinOphthalmol. 2010;21:468–72. - PMC - PubMed
    1. Asproudis I, Felekis T, Tsanou E, Gorezis S, Karali E, Alfantaki S, et al. Juvenile idiopathic arthritis-associated uveitis:Data from a region in western Greece. Clin Ophthalmol. 2010;4:343–7. - PMC - PubMed
    1. Woreta F, Thorne JE, Jabs DA, Kedhar SR, Dunn JP. Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol. 2007;143:647–55. - PMC - PubMed
    1. Doycheva D, Deuter C, Stuebiger N, Biester S, Zierhut M. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol. 2007;91:180–4. - PMC - PubMed

Substances